Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - HC Wainwright lifted their Q3 2026 EPS estimates for Climb Bio in a research note issued to investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.20) for the quarter, up from their prior forecast of ($0.23). HC Wainwright currently has a "Buy" rating and a $24.00 price objective on the stock. The consensus estimate for Climb Bio's current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Climb Bio's Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.98) EPS.
Climb Bio (NASDAQ:CLYM - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03.
Several other research firms have also commented on CLYM. Guggenheim began coverage on Climb Bio in a research report on Monday, June 8th. They set a "buy" rating and a $35.00 price target for the company. BTIG Research increased their target price on Climb Bio from $19.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday, June 11th. Chardan Capital initiated coverage on Climb Bio in a research note on Tuesday, May 5th. They set a "buy" rating and a $22.00 target price on the stock. Robert W. Baird set a $21.00 target price on Climb Bio in a report on Wednesday, May 6th. Finally, Royal Bank Of Canada assumed coverage on Climb Bio in a research report on Monday, August 3rd. They issued an "outperform" rating and a $23.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $23.08.
Read Our Latest Analysis on CLYM
Climb Bio Stock Up 8.8%
Shares of NASDAQ CLYM opened at $17.84 on Wednesday. The business's 50 day moving average is $13.59 and its two-hundred day moving average is $10.29. Climb Bio has a 52-week low of $1.54 and a 52-week high of $18.33. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -21.49 and a beta of 0.08.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in Climb Bio in the 2nd quarter valued at about $45,000. California State Teachers Retirement System acquired a new position in shares of Climb Bio during the second quarter worth about $82,000. Virtu Financial LLC purchased a new stake in shares of Climb Bio during the fourth quarter worth approximately $43,000. Blair William & Co. IL purchased a new stake in shares of Climb Bio during the fourth quarter worth approximately $44,000. Finally, Balyasny Asset Management L.P. acquired a new stake in Climb Bio in the fourth quarter valued at approximately $57,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.
About Climb Bio
(
Get Free Report)
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
